| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Plaque-type dura mater graft-associated Creutzfeldt-Jacob disease (p-dCJD) prions showed distinct amplification features from those of non p-dCJD (np-dCJD) prions in protein misfolding cyclic amplification (PMCA). Although no amplification from np-dCJD prions was observed with 129M or 129V substrates, p-dCJD prions were amplified drastically with the 129V substrates but not with the 129M substrates despite the PRNP codon 129 incompatibility between seed and substrate. Moreover, we found that type 2 PMCA products were newly generated from p-dCJD prions using type 2 PrPSc-specific antibody, while PrPSc in p-dCJD cases did not react with the type 2 PrPSc-specific antibody. These findings suggest that our PMCA is a useful tool for easily and rapidly identifying acquired CJD associated with the transmission of the V2 CJD strain of codon 129 methionine homozygotes, based on the preference for the 129 V substrate and the type of the amplified products.
|
